Next 10 |
home / stock / bnox / bnox articles
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-s...
Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post...
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX) (Bionomics or Company), a clinical-s...
A psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for ev...
Biopharma company Bionomics Ltd. (NASDAQ: BNOX) announced that, following an end-of-Phase 2 meeting with the Food and Drug Administration (FDA...
Steve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics Shares NY Mets owner Steve Cohen has bought as many as 119,092,680 ordinary...
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares climbed 86.1% to $0.2248 after the company said it is considering strategic alternatives ...
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategi...
Gainers Blue Apron Holdings, Inc. (NASDAQ: APRN) climbed 133.5% to $12.82 after the company announced an agreement to be acquired by Wonder Group ...
News, Short Squeeze, Breakout and More Instantly...
ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat pat...
ADELAIDE, Australia and CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nerv...
2024-03-21 07:55:00 ET DENVER, Colo., Mar 21, 2024 ( 247marketnews.com )- Bionomics Limited (NASDAQ: BNOX ) released, this morning, the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder. The full data analysis shows that ATTUNE ...